This article was originally published in The Gray Sheet
Beckman Coulter agrees to buy the remaining 80% of NexGen Diagnostics, which was spun off from Lumigen when Beckman Coulter bought Lumigen in 2006 (1"The Gray Sheet" Oct. 9, 2006, In Brief). NexGen's assets are intellectual property unrelated to current products. The technology will "simplify and automate certain types of immunodiagnostics and nucleic acid testing in remarkable ways, dramatically enhancing the performance of assays and accelerating turn-around time of test results," explains Richard Creager, VP of Beckman Coulter's Immunoassay Business Center. Beckman expects to take a charge of about $36 million for in-process R&D when the deal closes at the end of 2007
You may also be interested in...
Beckman Coulter gains access to Lumigen's technology for immunochemical and other high-sensitivity testing via its $185 mil. acquisition, expected to close by Nov. 1. Having partnered with Lumigen for more than 10 years, Beckman Coulter has already drawn from the company's well; Lumigen's chemiluminescent chemistry is the cornerstone of Beckman Coulter's Access family of immunoassay systems, the Oct. 2 release says...
No device-related warning letters were released by the US FDA the week of 31 March.
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.